Telix Pharmaceuticals Hits Key Milestone in Phase 3 Prostate Cancer Trial

Telix Pharmaceuticals (ASX: TLX) has reached a pivotal juncture in its oncology pipeline with the successful completion of Part 1 of the ProstACT GLOBAL Phase 3 trial. The study, which evaluates TLX591 (177Lu-rosopatamab tetraxetan) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), met its primary objectives, reinforcing the safety profile and dosimetry of the therapeutic candidate. This achievement is a significant de-risking event for Telix, as it validates the company’s unique approach to radiopharmaceutical therapy in a highly competitive market.

Unlike current market leaders that utilize small-molecule ligands to target the Prostate-Specific Membrane Antigen (PSMA), TLX591 employs a monoclonal antibody. This antibody-based approach is designed to increase the residence time of the radiopharmaceutical within the tumor microenvironment while potentially reducing off-target effects in the salivary and lacrimal glands—a common and often debilitating side effect associated with small-molecule PSMA therapies. By meeting the primary objectives in Part 1, Telix has demonstrated that its refined, fractionated dosing regimen is both safe and achieves the intended biodistribution in patients.

“

Telix Pharmaceuticals (ASX: TLX) has reached a pivotal juncture in its oncology pipeline with the successful completion of Part 1 of the ProstACT GLOBAL Phase 3 trial.

The radiopharmaceutical sector has seen explosive growth and consolidation recently, largely driven by the commercial success of Novartis's Pluvicto. Telix’s success in Part 1 of ProstACT GLOBAL positions TLX591 as a formidable challenger. The trial's design specifically targets the 'second-line' mCRPC setting, where patients have progressed after initial hormone therapy but before extensive chemotherapy. By moving earlier in the treatment paradigm, Telix aims to capture a larger patient population and provide a more tolerable alternative to standard-of-care treatments.

ProstACT GLOBAL is a multi-center, randomized controlled trial designed to provide the definitive data required for global regulatory filings. Part 1 was specifically focused on confirming the safety and dosimetry of the updated dosing schedule in a diverse global population. With these objectives met, the trial is now set to transition seamlessly into Part 2. This next phase will focus on the critical efficacy endpoints of radiologic progression-free survival (rPFS) and overall survival (OS) in a significantly larger cohort of patients. The transition marks a shift from safety validation to the demonstration of clinical superiority.